Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + GEMOX followed by lenvatinib for unresectable intrahepatic cholangiocarcinoma (single-arm, phase 2)
ChiCTR2500114197Phase 2Not yet recruiting
- Sponsor
- Tianjin Third Central Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epacadostat, oxaliplatin, gemcitabine and lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Third Central Hospital. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
epacadostatoxaliplatingemcitabinelenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500114197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114197.